498 related articles for article (PubMed ID: 25829086)
1. PET with Fluorodeoxyglucose F 18/Computed Tomography in the Clinical Management and Patient Outcomes of Esophageal Cancer.
Kwee RM; Marcus C; Sheikhbahaei S; Subramaniam RM
PET Clin; 2015 Apr; 10(2):197-205. PubMed ID: 25829086
[TBL] [Abstract][Full Text] [Related]
2. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
3. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
4. PET/Computed Tomography and Patient Outcomes in Melanoma.
Rohren EM
PET Clin; 2015 Apr; 10(2):243-54. PubMed ID: 25829089
[TBL] [Abstract][Full Text] [Related]
5. (18)F-FDG-PET/CT in assessing response to neoadjuvant chemoradiotherapy for potentially resectable locally advanced esophageal cancer.
Metser U; Rashidi F; Moshonov H; Wong R; Knox J; Guindi M; Darling G
Ann Nucl Med; 2014 May; 28(4):295-303. PubMed ID: 24474598
[TBL] [Abstract][Full Text] [Related]
6. The value of ¹⁸F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy.
Myslivecek M; Neoral C; Vrba R; Vomackova K; Cincibuch J; Formanek R; Koranda P; Zapletalova J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun; 156(2):171-9. PubMed ID: 22660205
[TBL] [Abstract][Full Text] [Related]
7. Incremental value of 18F-FDG PET/CT in therapeutic decision-making of potentially curable esophageal adenocarcinoma.
Purandare NC; Pramesh CS; Karimundackal G; Jiwnani S; Agrawal A; Shah S; Kulkarni M; Laskar SG; Rangarajan V
Nucl Med Commun; 2014 Aug; 35(8):864-9. PubMed ID: 24751701
[TBL] [Abstract][Full Text] [Related]
8. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
9. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer.
Laurens ST; Oyen WJ
PET Clin; 2015 Jul; 10(3):345-60. PubMed ID: 26099671
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.
Krause BJ; Herrmann K; Wieder H; zum Büschenfelde CM
J Nucl Med; 2009 May; 50 Suppl 1():89S-96S. PubMed ID: 19380406
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of 18F-FDG PET/CT and CT/MRI with histopathologic correlation in patients undergoing central compartment neck dissection for squamous cell carcinoma of the larynx, hypopharynx, and esophagus.
Kim JW; Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2013 May; 49(5):449-53. PubMed ID: 23321549
[TBL] [Abstract][Full Text] [Related]
12. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN
JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
[TBL] [Abstract][Full Text] [Related]
13. Lung cancer.
Akhurst T; MacManus M; Hicks RJ
PET Clin; 2015 Apr; 10(2):147-58. PubMed ID: 25829084
[TBL] [Abstract][Full Text] [Related]
14. Is diffusion-weighted MRI superior to FDG-PET or FDG-PET/CT in evaluating and predicting pathological response to preoperative neoadjuvant therapy in patients with rectal cancer?
Li YL; Wu LM; Chen XX; Delproposto Z; Hu JN; Xu JR
J Dig Dis; 2014 Oct; 15(10):525-37. PubMed ID: 25060294
[TBL] [Abstract][Full Text] [Related]
15. Assessment of relapse in patients with peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy using F-18-FDG-PET/CT.
Klumpp B; Schwenzer NF; Gatidis S; Koenigsrainer I; Koenigsrainer A; Beckert S; Mueller M; Claussen CD; Pfannenberg C
Rofo; 2014 Apr; 186(4):359-66. PubMed ID: 24683168
[TBL] [Abstract][Full Text] [Related]
16. Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy.
Tan S; Kligerman S; Chen W; Lu M; Kim G; Feigenberg S; D'Souza WD; Suntharalingam M; Lu W
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1375-82. PubMed ID: 23219566
[TBL] [Abstract][Full Text] [Related]
17. 18F-fluorodeoxyglucose PET/computed tomography and risk stratification after neoadjuvant treatment in esophageal cancer patients.
Cervino AR; Pomerri F; Alfieri R; Sileni VC; Castoro C; Galuppo S; Evangelista L
Nucl Med Commun; 2014 Feb; 35(2):160-8. PubMed ID: 24220054
[TBL] [Abstract][Full Text] [Related]
18. (18)F-Flourodeoxy-Glucose PET/Computed Tomography in Brain Tumors: Value to Patient Management and Survival Outcomes.
Wray R; Solnes L; Mena E; Meoded A; Subramaniam RM
PET Clin; 2015 Jul; 10(3):423-30. PubMed ID: 26099676
[TBL] [Abstract][Full Text] [Related]
19. FDG PET/CT in the management of colorectal and anal cancers.
Agarwal A; Marcus C; Xiao J; Nene P; Kachnic LA; Subramaniam RM
AJR Am J Roentgenol; 2014 Nov; 203(5):1109-19. PubMed ID: 25341152
[TBL] [Abstract][Full Text] [Related]
20. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
van Gool MH; Aukema TS; Schaake EE; Rijna H; Codrington HE; Valdés Olmos RA; Teertstra HJ; van Pel R; Burgers SA; van Tinteren H; Klomp HM
Ann Surg Oncol; 2014 Sep; 21(9):2831-7. PubMed ID: 24845729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
